<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080947</url>
  </required_header>
  <id_info>
    <org_study_id>0088/2019</org_study_id>
    <nct_id>NCT04080947</nct_id>
  </id_info>
  <brief_title>Evaluation the Safety and Efficacy of Montelukast in Treatment of Patients With Fatty Liver Disease</brief_title>
  <official_title>Evaluation the Safety and Efficacy of Montelukast in Treatment of Patients With Fatty Liver Disease: A Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sadat City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sadat City University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate the safety and efficay of Montelukast in
      treatment of patients with fatty liver disease.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The risks to human subjects unexpectedly outweigh the benefits
  </why_stopped>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic transaminases</measure>
    <time_frame>From baseline to 24 weeks</time_frame>
    <description>Alanine aminotransferase (ALT) and Aspartate Aminotransferase (AST) will be evaluated in U/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum ferritin</measure>
    <time_frame>From baseline to 24 weeks</time_frame>
    <description>Serum ferritin will be evaluated in µg/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>They will be dosed at baseline and after 24 weeks of intervention</time_frame>
    <description>Total cholesterol (mg/dL), LDL-cholesterol (mg/dL), HDL-cholesterol (mg/dL), VLDL-cholesterol (mg/dL) and triglycerides (mg/dL) will be measured before and after the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>They will be dosed at baseline and after 24 weeks of intervention</time_frame>
    <description>Fasting blood glucose (mg/dL) will be measured before and after the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated haemoglobin</measure>
    <time_frame>They will be dosed at baseline and after 24 weeks of intervention</time_frame>
    <description>Hb A1c (%) will be measured before and after the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>They will be dosed at baseline and after 24 weeks of intervention</time_frame>
    <description>Insulin (µU/mL) will be measured before and after the intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Iron</measure>
    <time_frame>They will be dosed at baseline and after 24 weeks of intervention</time_frame>
    <description>Serum iron (mcg/dL) will be measured before and after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferrin saturation</measure>
    <time_frame>They will be dosed at baseline and after 24 weeks of intervention</time_frame>
    <description>Transferrin saturation (%) will be measured before and after intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 patients will receive placebo (Control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients will receive montelukast 10 mg/ day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>patients received matching-image placebo once daily at bedtime for 24 weeks.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Montelukast group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast group</intervention_name>
    <description>patients received montelukast (10-mg chewable tablet) once daily at bedtime for 24 weeks.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Montelukast group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between 18 and 60 years of age, both men and women,

          -  Clinical diagnosis of NAFLD, confirmed by imaging exams,

          -  Patients who present levels above the reference values of ALT, AST and ferritin.

          -  Those who spontaneously agree to participate in the research, by signing the Term of
             Free and Informed Consent.

        Exclusion Criteria:

          -  Women in the menacing period, with the exception of those who have performed
             definitive sterilization, such as hysterectomy or tubal ligation.

          -  Patients with established prior diagnosis of chronic noncommunicable disease
             (congestive heart failure, decompensated or severe lung disease, neoplasms, renal
             disease, advanced liver disease - Child Pugh C classification)

          -  Patients with schistosomiasis;

          -  Hemochromatosis

          -  Wilson's disease

          -  Viral or autoimmune hepatitis

          -  HIV virus carriers

          -  Woman who is breastfeeding

          -  Users of illicit drugs

          -  Patients with an intake of more than 20 g / day of alcohol and / or past alcoholism
             with abstention less than 6 months;

          -  Patients with ingestion of medications such as steroids, estrogens, amiodarone,
             warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents
             in the last 6 months

          -  Patients with clinically manifest infections or inflammation, surgery, trauma or
             hospitalization in the last 30 days

          -  Chronic non-hepatic degenerative diseases (sclerosis, Parkinson's disease or
             -Alzheimer's disease)

          -  Patients who do not participate in all stages of the research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 31, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sadat City University</investigator_affiliation>
    <investigator_full_name>Mahmoud Samy Abdallah</investigator_full_name>
    <investigator_title>Lecturer of Clinical Pharmacy, PhD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

